The farnesyl-diphosphate farnesyltransferase gene has the potential to be used as a biomarker for the ccRCC diagnosis and to treat ccRCC by regulating ferroptosis (105). This evidence concerns the gene FDFT1 and nonpapillary renal cell carcinoma.